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Background: The roles of pharmacists have evolved from product oriented, dispensing of medications to more
patient-focused services such as the provision of pharmaceutical care. Such pharmacy service is also becoming
more widely practised in Malaysia but is not well documented. Therefore, this study is warranted to fill this
information gap by identifying the types of pharmaceutical care issues (PCIs) encountered by primary care patients
with diabetes mellitus, hypertension or hyperlipidaemia in Malaysia.
Methods: This study was part of a large controlled trial that evaluated the outcomes of multiprofessional
collaboration which involved medical general practitioners, pharmacists, dietitians and nurses in managing diabetes
mellitus, hypertension and hyperlipidaemia in primary care settings. A total of 477 patients were recruited by 44
general practitioners in the Klang Valley. These patients were counselled by the various healthcare professionals and
followed-up for 6 months.
Results: Of the 477 participants, 53.7% had at least one PCI, with a total of 706 PCIs. These included drug-use
problems (33.3%), insufficient awareness and knowledge about disease condition and medication (20.4%), adverse
drug reactions (15.6%), therapeutic failure (13.9%), drug-choice problems (9.5%) and dosing problems (3.4%).
Non-adherence to medications topped the list of drug-use problems, followed by incorrect administration of
medications. More than half of the PCIs (52%) were classified as probably clinically insignificant, 38.9% with minimal
clinical significance, 8.9% as definitely clinically significant and could cause patient harm while one issue (0.2%) was
classified as life threatening. The main causes of PCIs were deterioration of disease state which led to failure of
therapy, and also presentation of new symptoms or indications. Of the 338 PCIs where changes were
recommended by the pharmacist, 87.3% were carried out as recommended.
Conclusions: This study demonstrates the importance of pharmacists working in collaboration with other
healthcare providers especially the medical doctors in identifying and resolving pharmaceutical care issues to
provide optimal care for patients with chronic diseases.
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The roles of pharmacists have evolved from product
oriented, dispensing of medications to more patient-
focused services such as the provision of pharmaceutical
care, which includes the identification, prevention and
resolution of drug-related problems (DRPs). The term
“pharmaceutical care” was defined by Hepler and Strand
[1]. Basically, it is the responsible provision of drug ther-
apy by the collaboration of a clinical pharmacist with the
patient as well as other members of the healthcare team
in designing, implementing and monitoring a thera-
peutic plan that will produce specific outcomes.
DRPs are defined as “problems in the pharmacother-
apy of the individual patient that actually or potentially
interfere with desired health outcomes” [2]. Among the
most common DRPs are: adverse drug reactions, drug
choice problem, dosing problem, drug-use problem and
interactions [3]. Other terminology such as pharmaceut-
ical care issues (PCIs) has also been used [4].
Studies have shown that the cost associated with DRPs
far exceed the cost of medications. Ernst & Grizzle [5]
found that the estimated cost of morbidity and mortality
due to DRPs was more than USD177.4 billion yearly.
Wermeille and colleagues [6] reported PCIs resolved
by community pharmacists in collaboration with medical
general practitioners (GPs). Other studies reported a sig-
nificant reduction in HbA1c in community-based
patients with diabetes provided pharmaceutical care by a
pharmacist [7-12]. A systematic review conducted by
Royal and colleagues [13] showed that pharmacist-
initiated medication review was effective in reducing
hospital admission by 36%. However, most of the studies
on pharmaceutical care were conducted in countries
such as Australia, the United Kingdom and the United
States [6,7,14-20]. Studies in South East Asia are scarce
and therefore, this study is warranted to fill the informa-
tion gap by identifying the types of PCIs encountered by
primary care patients with diabetes mellitus, hyperten-
sion or hyperlipidaemia in Malaysia.
Methods
Study population
This study was part of a large controlled trial called the
Cardiovascular Risk Factors Intervention Strategies
(CORFIS) trial. The CORFIS trial was a community-
based, multicentre trial which compared the impact of
collaborative intervention by various healthcare profes-
sionals (GPs, pharmacists, dietitians and nurses) to usual
standard care on patients with diabetes, hypertension or
hyperlipidaemia. All the patients in the intervention
group of the CORFIS trial were included in this part of
the study. Patients in the control group were not
included in this part of the study because under the
usual healthcare practice in Malaysia, patients who seektreatment in GP clinics obtained their medications from
the clinic itself and do not have to see a pharmacist. The
study was approved by the Medical Research Ethics
Committee of the Ministry of Health Malaysia.
Participants were recruited from 44 GP clinics in the
Klang Valley, Malaysia from January to June 2008. The
Klang Valley encompasses Kuala Lumpur and its vicinity
which constitutes the main commercial and administra-
tive centre in Malaysia. Inclusion criteria of patients
were: participants aged 18 and above, with at least one of
the following diseases: diabetes mellitus, hypertension or
hyperlipidaemia, and currently managed with at least one
medication. Exclusion criteria were those who did not
provide written consent, were pregnant or breast-feeding,
had history of unstable angina, heart failure, acute myo-
cardial infarction, clinically significant valvular heart
disease, stroke, coronary revascularization procedure, or
who had serum creatinine of more than 150 mmol/L in
the preceeding 6 months, or were not able to visit the
clinics for monthly follow-up sessions. Written informed
consent for participation in the study was obtained from
all participants.
Study procedures
The study involved a group of pharmacists, dietitians
and nurses. Each participant was interviewed and coun-
selled by one of the pharmacists, dietitians and nurses
at the GP clinic where the participant was recruited
(Figure 1). Each participant spent about 30 to 60 min
with each of the healthcare providers. In this study, the
term PCIs was used instead of DRPs to cover a wider
spectrum of issues and also because pharmaceutical
care was provided by service pharmacists to the partici-
pants. During the 24-week follow-up assessments, the
pharmacist reviewed the participants’ medications and
counselled the participants every 4 weeks, noted any
PCIs encountered by the participants and helped to re-
solve the PCIs. If required, the pharmacist would con-
tact the GP concerned to alert, discuss and if possible,
to resolve the PCIs which could affect the participants’
clinical outcomes. Whereas, the dietitians provided diet-
ary advice while the nurses advised the patients on gen-
eral healthcare such as foot care.
Outcome measures
The primary outcome was the types of PCIs encoun-
tered by the participants, as identified by the pharma-
cists. The secondary outcomes were the causes and
clinical significance of the PCIs, and outcome of the
interventions made by the pharmacists.
Data analysis
All data collected were analysed using the Statistical
Package for Social Sciences (SPSS Inc., Chicago, IL,
Assessed by GP concerned Assessed by GP concerned
Seen by one of the nurses 
Counselled by one of the dietitians 
Reviewed and counselled by one of the pharmacists 
Analyzed (n= 477)
Allocated to CORFIS arm (n = 527)
Withdrew consent      (n = 50)     




Screening by GP for 
eligible participants
(n = 884)
Allocated to usual care   (n = 257)
Withdrew consent    (n=29) 
Received usual care    (n = 228)
Figure 1 Flow chart of the CORFIS study.
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all data. Sample means and standard deviations (SDs)
were presented for continuous variables while frequen-
cies and percentages were calculated for categorical vari-
ables. All outcome measures were classified by two
pharmacists who were involved with the design and con-
duct of the study hence, were very familiar with the PCIs
identified. However, to prevent bias, the clinical signifi-
cance of the PCIs was classified independently by a clin-
ician and another pharmacist who were not involved in
the study. All classifications were based on “The PCNE
Classification V 5.01” [3] except for the outcome of
interventions and the clinical significance of the PCIs.
Some additional categories of classification were added
to cover the broad spectrum of PCIs encountered in this
study as some could not be put under the categories
specified by the PCNE.
Clinical significance of the PCIs was classified based
on the four categories used by Stubbs et al. [21]: Grade
(1) probably clinically insignificant, (2) minimal clinical
significance, (3) definitely clinically significant and could
cause patient harm and (4) potentially life-threatening.
These PCIs were initially classified independently by a
clinician and a pharmacist. The results were tested for
correlation using Kappa statistics, κ. The strength of
agreement is as followed: κ < 0.20 is poor, 0.21–0.40 is
fair, 0.41-0.60 is moderate, 0.61-0.80 is good and 0.81-1.00
is very good [22]. A consensus on the final classificationwas derived with the assistance of another clinician and
another pharmacist.Results
A total of 477 participants in the CORFIS arm were
included in this part of the study. The demographic
data and baseline characteristics of these participants
are shown in Table 1. Of the 477 participants, 268
(56.2%) had diabetes mellitus, 320 (67.1%) had hyper-
tension, and 299 (62.9%) had hyperlipidaemia. These
three chronic diseases often occurred together, with
311 participants (65.2%) who had either diabetes with
hypertension, diabetes with hyperlipidaemia, hyperten-
sion with hyperlipidaemia or all the three diseases.Pharmaceutical Care Issues
Of the 477 participants, 53.7% (256 participants) had at
least one PCI, giving a total of 706 issues. Details of the
PCIs encountered by the participants are shown in
Table 2.
Non-adherence to medications was the most common
drug-use problem (146 of 235 issues, 62.1%). Other
drug-use problems involved participants administrating
their medications at incorrect doses or frequencies or in-
correct timing with respect to meals. For example, met-
formin and aspirin were taken before meals and
sulphonylureas were taken at bedtime.
Table 1 Demographics and clinical characteristics of
participants recruited at baseline
Characteristics Intervention (n = 477)














Cardiovascular comorbidities, frequency (%)
Diabetes (DM) 45 (9.4)
Hypertension (HPT) 79 (16.6)
Hyperlipidaemia (HLP) 42 (8.8)
DM + HPT 54 (11.3)
DM + HLP 70 (14.7)
HPT + HLP 88 (18.4)
DM + HPT + HLP 99 (20.8)
Smoking history, frequency (%)
Yes 74 (15.5)
No 403 (84.5)
Note: DM Diabetes mellitus, HPT Hypertension, HLP Hyperlipidaemia.
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ledge” included 47 issues pertaining to the misconcep-
tion of participants concerning the use of medications
and participants’ lack of knowledge and queries about
their medications and also their disease states. Fifteen
issues were related to participants’ undue worries about
the side effects and complications related to their medi-
cations and another 82 issues of unclear complaints
concerning some health problems which may be related
to patients’ medications were also included in this
category.
Adverse drug reactions (ADRs) included side effects
of medications as reported by the participants. Exam-
ples of these side effects are as shown in Table 2.
Hypoglycaemia was related to the use of antidiabetic
agents. Gastrointestinal disturbances included gastritis
due to non-steroidal anti-inflammatory drugs (NSAIDs)
and diarrhoea associated with the use of metformin
(6 cases each). Another 12 participants complained ofdry cough attributed to the use of angiotensin-
converting enzyme inhibitors while 10 participants
complained of muscle aches and cramps after using
statins. ADRs classified as “Others” included dermato-
logical reactions such as eczema, rashes and itch;
weight gain; frequent urination; hair loss; bradycardia;
bleeding from the anus; blocked nose and flushing.
Therapy failure was assumed when participants’ blood
pressure (BP), blood glucose levels or lipid levels were
not at target levels despite being on pharmacological
treatment. Whereas, drug choice problem in this study
involved participants who had been seen by the GPs but
still with high BP, high blood glucose or high cholesterol
level and were not on any medications. Inappropriate
duplication of therapeutic group or active ingredient
involved two participants who were given both glimepir-
ide and gliclazide, another participant was given glicla-
zide 80 mg (DiamicronW) and modified-release gliclazide
30 mg (Diamicron MRW) while another participant was
given irbesartan (ApprovelW) and a combination of irbe-
sartan and hydrochlorothiazide (Co-ApprovelW). In
addition, one participant was on both loratadine and
desloratadine. The only case of contraindication encoun-
tered in this study involved a woman planning to get
pregnant but was prescribed a combination of irbesartan
and hydrochlorothiazide (Co-ApprovelW) [23].
Dosing problems included doses and frequencies of
medications prescribed which were either too high or
too low. Two cases with problems in the duration of
treatment involved a participant given a statin for
only a week and another who was still prescribed
a statin even though his cholesterol level was only
2.9 mmol/L and his low-density lipoprotein (LDL) was
1.3 mmol/L.
Dispensing issues involved incorrect labeling of the dos-
age or frequency of antidiabetic drugs. There were two
cases where the strength of enalapril was wrongly stated
on the label. Another case involved atorvastatin (StorvasW)
being labeled as simvastatin. In addition, a participant was
prescribed irbesartan (ApprovelW) but was dispensed
irbesartan and hydrochlorothiazide (Co-ApprovelW).
Another participant was dispensed 40 mg of atorvasta-
tin although was prescribed only 10 mg. This subclass
of PCIs also included two cases of inappropriate storage
of medication. Glyceryl trinitrate (GTN) was dispensed
in a plastic envelope instead of its original bottle. Atovar-
statin was kept in a plastic envelope and the colour of
the tablets had changed. These PCIs were brought to the
attention of the GPs or clinic staff concerned to prevent
repetition of such issues.
Potential drug interactions included the use of enala-
pril with allopurinol which may increase the risk of
leucopenia and hypersensitivity induced by allopurinol;
fenofibrate and atorvastatin which may increase the risk
Table 2 Categories of PCIs according to PCNE V5.01 classification
No. Primary domain Code Sub-classes Frequency (%)
1 Adverse drug reactions P1.1 Hypoglycaemia 19 (2.7)
Gastrointestinal disturbances 19 (2.7)
Cough 13 (1.8)




2 Drug choice problems P2.1 Inappropriate drug 6 (0.8)
P2.3 Inappropriate duplication 5 (0.7)
P2.4 Contraindication 1 (0.1)
P2.5 No clear indication for drug 10 (1.4)
P2.6 No drug prescribed but clear indication 41 (5.8)
P2.7 Inadequate regimen 3 (0.4)
P2.8 Drug not required 1 (0.1)
Subtotal 67 (9.5)
3 Dosing problem P3.1 Dose too low or frequency not enough 10 (1.4)
P3.2 Dose too high or frequency too often 10 (1.4)
P3.3 Duration of treatment too short 1 (0.1)
P3.4 Duration of treatment too long 1 (0.1)
P3.5 Inappropriate dosing 2 ((0.3)
Subtotal 24 (3.4)
4 Drug use problems P4.1 Drug not taken or administered at all 20 (2.8)
P4.3 Incorrect administration 69 (9.8)
P4.4 Non-adherence to medication 146 (20.7)
Subtotal 235 (33.3)
5 Drug interaction P5.1 Potential interaction 4 (0.5)
6 Others P6.2 Insufficient awareness/knowledge 144 (20.1)
P6.3 Unclear complaints 82 (11.6)
P6.4 Therapy failure 98 (13.9)
P6.5 Worries about complications/ADRs 15 (2.1)
P6.6 Dispensing issues 11 (1.6)
P6.7 Lifestyle modifications 8 (1.1)
P6.8 Monitoring for side effects 3 (0.4)
P6.9 Technical issues 2 (0.3)
TOTAL 706 (100)
*Subclasses added, not in The PCNE Classification V 5.01.
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which may increase the risk of liver problems [23,24].
The eight cases of lifestyle modifications included par-
ticipants who were current smokers and were counselled
on smoking cessation. There were several cases where
participants asked about diet and exercise but these were
referred to the dietitian and not considered as PCIs.
Monitoring of side effects included alerting the doctors
to monitor participants’ liver function for those onstatins and blood glucose level in a patient suspected to
have diabetes.
Classification of PCIs according to clinical significance
A Cohen’s Kappa statistic (k) of 0.729 (P = 0.036) was
obtained which implied good agreement in classification
between the two assessors. Of the 706 PCIs, 52% were
classified as probably clinically insignificant, 38.9% with
minimal clinical significance, 8.9% as definitely clinically
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(0.2%) where a participant reported bleeding from the
anus attributed to the use of aspirin was classified as life
threatening.
Causes of PCIs
Causes of PCIs are as shown in Table 3. Non-adherence
to medications was attributed to forgetfulness or to par-
ticipants having doubts or misconception about the pur-
pose and effectiveness of their medications. Some
participants reported that they were not clear regarding
the dosage and use of their medications while others
were unwilling to take their medications due to fear of
side effects.
Outcome of pharmacist intervention
The most common intervention made by the pharma-
cists was the counselling of patients on their medica-
tions (38.8%), followed by the referral of patients to the
prescribers (20.8%), educating patients concerning their
disease states (12.0%), recommending a change in the
dose or frequency of the medications or to add another
medication (5.8%) and to monitor the patient’s condition
(5.0%).
The outcome of pharmacist intervention is as shown
in Table 4. If the PCIs with “unknown outcomes” and
“no change required” categories were excluded, then
87.3% (295 out of 338) of changes were made as recom-
mended by the pharmacist. No change was made when
the prescriber or patient preferred to continue monitor-
ing the patient’s condition or to wait until the next clinic
appointment before making any changes. Majority of
pharmacist interventions were directed at the patients
(496 of 702; 70.9%) with only 29.1% (204 of 702) that
involved the medical doctors. One of the PCIs required
action to be taken by the caregiver and another by the
clinic staff. If “unknown outcomes” and “no change
required” were excluded, 77.9% of changes recom-
mended by the pharmacists were accepted by the doc-
tors. However, 91.5% of changes recommended by the
pharmacists were carried out by the patients.
Discussion
This study is probably the first large scale trial con-
ducted in Malaysia which involved collaboration
between various healthcare professionals in the manage-
ment of diabetes, hypertension or hyperlipidaemia at pri-
mary care level. More than half of the participants
encountered at least one PCI, with a total of 706 PCIs
identified.
Drug-use problems (especially non-adherence to medi-
cation), ADRs, therapeutic failure and drug-choice pro-
blems constituted the main PCIs encountered by
participants in this study, followed by insufficientawareness or knowledge of participants. Wermeille and
colleagues [6] reported similar results. The high number of
PCIs encountered by the participants indicates the import-
ance of pharmacists working in collaboration with other
healthcare providers to identify and resolve such problems.
These include educating participants on the purpose and
side effects of medications to clear their doubts and mis-
conception, which would lead to better understanding and
hence better medication adherence [25].
Participants were taking their medications incorrectly
in terms of dose, frequency and timing in relation to
meals (8.2% of the PCIs). This again indicates that the
provision of pharmaceutical care is essential to identify
and resolve such problems in order to achieve optimal
clinical outcomes and also to reduce side effects such as
gastrointestinal disturbances.
Therapy failure constitutes 13.9% of the PCIs. The
usual recommendations for such issues were to increase
the dose or frequency of existing medication or to add
another medication. Patients were also advised to moni-
tor their BP or blood glucose level where appropriate.
Constant monitoring of BP, blood glucose levels and
lipid profile is crucial to ensure that these clinical con-
ditions are within target levels in order to prevent
complications and to reduce morbidity and mortality
[26,27]. In addition, lifestyle modification was also
often recommended.
The 11 dispensing issues identified in this study are
not reflective of the incidence of dispensing problems
encountered as this study was not designed specifically
to determine dispensing errors, hence no direct observa-
tion of the dispensing process was carried out. Examples
of dispensing errors noted in this study only served to
alert the healthcare professionals, especially those
involved in dispensing of medications at the primary
care clinics, that such errors may occur and measures
should be taken to minimize such risk.
Drug choice and dosing problems are usually detected
via double-checking by an independent person. Pharma-
cists can act as a safety net to prevent or minimize any
potential medication errors. These included a case of
contraindication which involved a woman planning to
get pregnant but was prescribed an angiotensin-receptor
blocker which carries a potential risk of teratogenesis if
the woman did get pregnant [23]. Again, the number of
prescribing discrepancies that were identified is not indi-
cative of the incidence of such problems as prescriptions
issued to participants of this study were not screened
individually.
Most of the PCIs were considered to be of no direct
potential clinical significance (52%), especially non-
adherence to medications and some minor side effects,
but they could cause inconvenience and prolongation of
the issues may lead to complications and increased cost
Table 3 Causes of PCIs (using The PCNE Classification V 5.01)
Primary domain Code V5.01 Cause Frequency (%, n = 706)
1. Drug/Dose selection C1.1 Inappropriate drug selection 7 (1.0)
C1.2 Inappropriate dosage selection 10 (1.4)
C1.3 More cost-effective drug available 2 (0.3)
C1.4 Pharmacokinetic problems, include ageing/
deterioration in organ function and interactions
5 (0.7)
C1.5 Synergistic/preventive drug required and not given 11 (1.6)
C1.6 Deterioration/improvement of disease state 150 (21.2)
C1.7 New symptom or indication revealed/presented 75 (10.6)
C1.8 Manifest side effect, no other cause 93 (13.2)
Subtotal 1 353 (50.0)
2. Drug use process C2.1 Inappropriate timing of administration and/or dosing intervals 44 (6.2)
C2.2 Drug underused/ under-administered 5 (0.7)
C2.3 Drug overused/ over-administered 9 (1.3)
C2.6 Patient unable to use drug/form as directed 2 (0.3)
C2.7 Too many medications* 6 (0.8)
C2.8 Inappropriate duration of use* 1 (0.1)
C2.9 New drug prescribed* 2 (0.3)
Subtotal 2 69 (9.8)
3. Information C3.1 Instructions for use/taking not known 2 (0.3)
C3.2 Patient unaware of reason for drug treatment 16 (2.3)
C3.5 Lack of communication between HCPs 1 (0.1)
C3.6 Miscommunication between doctor and patient* 4 (0.6)
C3.7 Unclear label* 6 (0.8)
Subtotal 3 29 (4.1)
4. Patient/Psychological C4.1 Patient forgets to use/take drug 34 (4.8)
C4.2 Patient has concerns with drugs 24 (3.4)
C4.3 Patient suspects side effects 37 (5.2)
C4.4 Patient unwilling to carry financial cost 6 (0.8)
C4.7 Patient unwilling to adapt life-style 3 (0.4)
C4.8 Burden of therapy 3 (0.4)
C4.9 Treatment not in line with health beliefs 6 (0.8)
C4.11 Religious belief* 6 (0.8)
C4.12 Patient unaware of possible complications* 8 (1.1)
C4.13 Patient unaware of drug name* 5 (0.7)
C4.14 Out of medication* 7 (1.0)
C4.15 Overseas or travelling* 9 (1.3)
C4.16 Patient smoking* 7 (1.0)
C4.17 Patient unaware of tablet strength* 1 (0.1)
C4.18 Patient does not trust HCPs* 1 (0.1)
C4.19 Patient on traditional medicine* 1 (0.1)
C4.20 Patient on too many supplements* 3 (0.4)
C4.21 Patient’s meal time is different* 1 (0.1)
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Table 3 Causes of PCIs (using The PCNE Classification V 5.01) (Continued)
C4.22 Patient shared medications 1 (0.1)
C4.23 Non-adherence to medications* 65 (9.2)
Subtotal 4 228 (32.3)
5. Logistics C5.2 Prescribing error (only in case of slip of the pen) 1 (0.1)
C5.3 Dispensing error (wrong drug or dose dispensed) 1 (0.1)
Subtotal 5 2 (0.3)
6. Others C6.11 Patient anxious about glucose level* 1 (0.1)
C6.12 Patient not sure of using glucose meter or other devices* 2 (0.3)
C6.13 Wrong frequency of glucose monitoring* 1(0.1)
C6.14 Drug stored in unsuitable condition* 2 (0.3)
C6.15 Patient not on medication in record* 3 (0.4)
C6.2 No obvious cause 16 (2.3)
Subtotal 6 25 (3.5)
*Subclasses added, not in The PCNE Classification V 5.01.
HCPs = Healthcare professionals.
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were considered to have minimal clinical significance,
except for aspirin which has a higher risk of causing
gastrointestinal complications and thus was classified as
definitely clinically significant.
The main causes of PCIs were deterioration or im-
provement of disease state which led to therapy failure,
and also presentation of new symptoms or indication.
This indicates the role of pharmacists in monitoring
patients with chronic diseases. The manifestation of
side effects such as cough, gastrointestinal problems
and symptoms of hypoglycaemia as well as patients’
concerns with drugs and undue worries about side
effects were also common causes of PCIs. In these
aspects, counselling of patients by the pharmacist is
important to resolve some of the preventable side
effects and also to assure and increase patients’ confi-
dence concerning their medications. Consequently,
educating and counselling patients on their medica-
tions and disease states were the main interventionsTable 4 Outcome of interventions
Outcome of interventions Freque
GP
Change made as per pharmacist recommendation 81 (77.9
Change made not as per pharmacist recommendation 1 (1.0)
No change made, medication not dispensed 1 (1.0)
No change made 21 (20.2
Subtotal 104
No change required 11
Outcome unknown 89
Total 204
Note: Four of the PCIs did not mention the action taken by the pharmacist to resol
total number of PCIs which involved the GPs and the patients was only 700 as two
shown in Table 4.made by the pharmacists (50.8%) in this study. Often,
patients were referred to the prescribers (20.8%) espe-
cially if adjustment to patients’ prescribed medication
regimens were deemed necessary.
In this study, most of the recommendations made by
the pharmacists (87.3%) were carried out accordingly. This
indicates the effectiveness of the pharmacist interventions
in resolving PCIs as well as the doctor and patients’ confi-
dence in following the recommendations made by phar-
macists. Other studies have also shown that pharmacist
interventions produced positive outcomes [13,28,29] and
well accepted by the doctors and patients [6].
This study has several strengths. The CORFIS trial was
performed in private primary care settings in Malaysia,
highlighting the feasibility of collaboration between phar-
macists, GPs, dietitians, nurses and patients in diabetes,
hypertension and hyperlipidaemia risk management. The
study had an adequate sample size and follow-up dur-
ation. It is probably the first study in Malaysia, which
involved the collaboration of various healthcarency (% of subtotal) Frequency (%, n = 702*)
Patient Overall
) 214 (91.5) 295 (42.0)
2 (0.9) 3 (0.4)
0 (0) 1 (0.1)





ve the issues and hence the total PCIs in Table 4 is only 702*. However, the
of the PCIs which required action by the clinic staff or the caregiver are not
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chronic diseases.
There are also several limitations in this study. The
process of detecting and resolving PCIs is very time con-
suming since there is a time-lag between identification
and subsequently communicating the PCI to the care-
giver involved, especially in a community setting. Poten-
tial bias in the detection and resolving of PCIs may exist
since this depended heavily on the experience of the
pharmacist performing the medication review. The clas-
sification of the PCIs, causes and outcomes were per-
formed by two pharmacists based on the information
recorded by the service pharmacist. Although care has
been taken to be as accurate as possible in the classifica-
tion, some ambiguities could not be ruled out. In
addition, the classification of the clinical significance of
the PCIs identified was not re-tested.
Conclusions
This study identifies the types of PCIs encountered by
patients with diabetes, hypertension or hyperlipidaemia.
It also demonstrates the importance of pharmacists
working in collaboration with other healthcare providers
especially the GPs, in resolving these PCIs to provide
optimal care for patients with chronic diseases.
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